Chimeric Therapeutics Limited (ASX:CHM)
Australia · Delayed Price · Currency is AUD 0.0110
-0.0020 (-15.38%)
Aug 26, 2026, 4:10 PM AEST
Chimeric Therapeutics Balance Sheet
Financials in millions AUD. Fiscal year is July - June.
Millions AUD. Fiscal year is Jul - Jun.
Assets
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Jun '25 Jun 30, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 | Jun '21 Jun 30, 2021 |
Cash & Equivalents | 2.5 | 5.76 | 3.05 | 2.36 | 18.38 | 22.41 |
Cash & Short-Term Investments | 2.5 | 5.76 | 3.05 | 2.36 | 18.38 | 22.41 |
Cash Growth | -50.60% | 88.58% | 29.22% | -87.15% | -17.98% | 22410099.00% |
Accounts Receivable | - | 4.55 | 0.09 | 6.66 | 0.04 | - |
Other Receivables | 2.53 | - | - | - | 2.62 | 0.02 |
Receivables | 2.53 | 4.55 | 0.09 | 6.66 | 2.66 | 0.02 |
Other Current Assets | 0.09 | 0.22 | 0.08 | 0.33 | 0.13 | 0.23 |
Total Current Assets | 5.13 | 10.53 | 3.22 | 9.35 | 21.17 | 22.67 |
Property, Plant & Equipment | - | - | 0 | 0.01 | 0.02 | 0.01 |
Long-Term Investments | - | - | 0.04 | 0.04 | 0.04 | - |
Other Intangible Assets | 0.8 | 11.04 | 12.01 | 12.98 | 13.65 | 13.83 |
Total Assets | 5.93 | 21.57 | 15.27 | 22.38 | 34.88 | 36.5 |
Liabilities
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Jun '25 Jun 30, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 | Jun '21 Jun 30, 2021 |
Accounts Payable | 5.82 | 6.57 | 3.2 | 7.41 | 4.7 | 2.04 |
Accrued Expenses | 0.78 | 1.75 | 3.24 | 3.77 | 1.83 | 1.06 |
Other Current Liabilities | 0.79 | 6.3 | 3.66 | 3.52 | 2.49 | 4.26 |
Total Current Liabilities | 7.38 | 14.61 | 10.1 | 14.69 | 9.02 | 7.35 |
Pension & Post-Retirement Benefits | 0 | 0 | - | - | - | - |
Other Long-Term Liabilities | 1.57 | 4.98 | 2.71 | 2.02 | 0.15 | 4.02 |
Total Liabilities | 8.96 | 19.6 | 12.8 | 16.71 | 9.17 | 11.37 |
Shareholders' Equity
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Jun '25 Jun 30, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 | Jun '21 Jun 30, 2021 |
Common Stock | 77.48 | 70.16 | 63.51 | 53.93 | 51.81 | 37.37 |
Retained Earnings | -87.55 | -76.33 | -66.56 | -56.78 | -30.86 | -15.18 |
Comprehensive Income & Other | 7.04 | 8.15 | 5.52 | 8.51 | 4.76 | 2.94 |
Shareholders' Equity | -3.03 | 1.97 | 2.47 | 5.66 | 25.71 | 25.13 |
Total Liabilities & Equity | 5.93 | 21.57 | 15.27 | 22.38 | 34.88 | 36.5 |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Jun '25 Jun 30, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 | Jun '21 Jun 30, 2021 |
Net Cash (Debt) | 2.5 | 5.76 | 3.05 | 2.36 | 18.38 | 22.41 |
Net Cash Growth | -50.60% | 88.58% | 29.22% | -87.15% | -17.98% | - |
Net Cash Per Share | 0.10 | 0.43 | 0.44 | 0.55 | 5.11 | 12.32 |
Filing Date Shares Outstanding | 41.09 | 32.55 | 9.05 | 5.29 | 4.25 | 3.31 |
Total Common Shares Outstanding | 41.09 | 20.15 | 8.76 | 5.07 | 4.25 | 3.31 |
Working Capital | -2.26 | -4.09 | -6.87 | -5.34 | 12.15 | 15.31 |
Book Value Per Share | -0.07 | 0.10 | 0.28 | 1.12 | 6.04 | 7.60 |
Tangible Book Value | -3.83 | -9.07 | -9.54 | -7.32 | 12.05 | 11.3 |
Tangible Book Value Per Share | -0.09 | -0.45 | -1.09 | -1.44 | 2.83 | 3.42 |